TissueTech said today that it added another $15 million to its coffers, led by prior backers River Cities Capital Funds and Ballast Point Ventures.
Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business).
The company raised a $10 million round back in 2013. The latest funding is earmarked for sales, marketing and R&D for its subsidiaries, TissueTech said.
Chairman & chief scientific officer Dr. Scheffer Tseng founded TissueTech in 2001 with his wife, Amy Tseng, the medical device company’s president & CEO.
“Ballast Point and River Cities have been tremendously supportive over the last two years. This additional round of equity funding will further support our commercial and enterprise infrastructure,” Amy Tseng said today in prepared remarks.
“Additionally, this funding will help support our clinical research and support our efforts to expand our product pipeline with innovative regenerative tissue therapies,” Scheffer Tseng added.
